Reportlinker Adds Endometriosis - Pipeline Assessment and Market Forecasts to 2017

Aug 31, 2010, 11:55 ET from Reportlinker

NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Endometriosis - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0286179/Endometriosis---Pipeline-Assessment-and-Market-Forecasts-to-2017.html

Endometriosis - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, "Endometriosis - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global endometriosis market. The report identifies the key trends shaping and driving the global endometriosis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global endometriosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global endometriosis market was valued at $785m in 2009 and will grow at a Compound Annual Growth Rate (CAGR) of 4.3% to reach $1.1 billion by 2017. This modest growth forecast is primarily attributed to a weak pipeline landscape. The existing market is weak due to a lack of diagnostic techniques, disease awareness and the poor safety and efficacy profiles of the existing therapies. There is a high unmet need which is largely driven by the availability of drugs that are moderately successful in terms of safety and efficacy. The endometriosis market is primarily formed of generic and off-label drugs and has very few approved drugs which fall in the major therapeutic categories such as NSAIDs, oral contraceptives, GnRH agonists and progestins

Scope

The report provides information on the key drivers and challenges of the endometriosis market. Its Scope includes:

- Annualized global endometriosis market revenues data from 2001 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as GnRH antagonists, GnRH synergists, aromatase inhibitors, antiprogestins and steroid sulfatase inhibitors.

- Analysis of the current and future competition in the global endometriosis market. Key market players covered are Bayer Healtcare Pharmaceuticals, Pfizer Inc, Neurocrine Biosciences Inc., AEterna Zentaris Inc. and Repros Therapeutics Inc.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the endometriosis therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global endometriosis market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global endometriosis market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global endometriosis market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Endometriosis: Introduction 4

2.1 GlobalData Pipeline Report Guidance 4

3 Endometriosis: Market Characterization 5

3.1 Endometriosis Therapeutics Market Size 5

3.2 Endometriosis Therapeutics Market Forecast and CAGR 6

3.3 Drivers and Barriers for the Endometriosis Therapeutics Market 7

3.3.1 Drivers for Endometriosis Therapeutics Market 7

3.3.2 Barriers for the Endometriosis Therapeutics Market 8

3.4 Opportunity and Unmet Need 8

3.5 Key Takeaway 9

4 The Endometriosis Therapeutics Market: Competitive Assessment 10

4.1 Overview 10

4.2 Strategic Competitor Assessment 10

4.3 Major Therapies in the Endometriosis Therapeutics Market 11

4.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for Endometriosis 11

4.3.2 Gonadotropin-Releasing Hormone (GnRH) agonists 11

4.3.3 Birth Control Hormones for Endometriosis 13

4.3.4 Progestins for Endometriosis 13

4.3.5 Danazol 14

4.4 Key Takeaway 15

5 Endometriosis Therapeutics Market: Pipeline Assessment 16

5.1 Overview 16

5.2 Strategic Pipeline Assessment 16

5.2.1 Technology Trends Analytic Framework 16

5.3 Endometriosis Therapeutics – Promising Drugs Under Clinical Development 17

5.4 Molecule Profile for Promising Drugs under Clinical Development 18

5.4.1 Visanne 18

5.4.2 Proellex 18

5.4.3 Elagolix (NBI-56418) 19

5.4.4 MPI-676 20

5.5 Endometriosis Therapeutics Market – Clinical Pipeline by Mechanism of Action 21

5.6 Endometriosis Disease Pipeline – Pipeline by Phase of Clinical Development 21

5.6.1 Endometriosis Therapeutics – Phase III and Regulatory Filed Clinical Pipeline 22

5.6.2 Endometriosis Therapeutics – Phase II Clinical Pipeline 22

5.6.3 Endometriosis Therapeutics – Phase I Clinical Pipeline 22

5.6.4 Endometriosis Therapeutics – Preclinical Pipeline 22

5.7 Key Takeaway 23

6 Global Endometriosis Therapeutics Market: Implications for Future Market Competition 24

7 Endometriosis: Future Players in Endometriosis therapeutics market 25

7.1 Introduction 25

7.2 Bayer AG 25

7.2.1 Company Overview 25

7.2.2 Business Description 26

7.3 Pfizer Inc. 27

7.3.1 Company Overview 27

7.3.2 Business Description 28

7.4 Æterna Zentaris Inc. 29

7.4.1 Company Overview 29

7.4.2 Business Description 29

7.5 Neurocrine Biosciences, Inc. 30

7.5.1 Company Overview 30

7.5.2 Business Description 30

7.6 Repros Therapeutics, Inc 31

7.6.1 Company Overview 31

7.6.2 Business Description 31

7.7 Meditrina Pharmaceuticals, Inc. 32

7.7.1 Company Overview 32

8 Global Endometriosis Therapeutics Market: Appendix 33

8.1 Definitions 33

8.2 Scope of Pipeline Research 33

8.3 Acronyms 33

8.4 Research Methodology 34

8.4.1 Coverage 34

8.4.2 Secondary Research 34

8.4.3 Forecasting 34

8.4.4 Primary Research 37

8.4.5 Expert Panels 37

8.5 Contact Us 37

8.6 Disclaimer 38

8.7 Sources 38

1.1 List of Tables

Table 1: Endometriosis Therapeutics Market, Global, Revenue ($m), 2001–2009 6

Table 2: Endometriosis Therapeutics Market, Global, Market Forecasts ($m), 2009–2017 7

Table 3: Endometriosis Therapeutics – Most Promising Drugs Under Clinical Development, 2010 17

Table 4:Endometriosis Therapeutics – Phase III & Approved Clinical Pipeline, 2010 22

Table 5: Endometriosis Therapeutics – Phase II Clinical Pipeline, 2010 22

Table 6: Endometriosis Therapeutics – Phase I Clinical Pipeline, 2010 22

Table 7: Endometriosis Therapeutics – Preclinical Pipeline, 2010 22

Table 8: Bayer AG – Women's Healthcare Pipeline Products, 2010 27

Table 9: Bayer AG – Endometriosis Pipeline Products, 2010 27

Table 10: Pfizer Inc – Women's Health Pipeline Products, 2010 29

Table 11: Pfizer Inc – Endometriosis Pipeline Products, 2010 29

Table 12: AEterna Zentaris Inc. – Endometriosis Pipeline Products, 2010 30

Table 13: Neurocrine Biosciences, Inc. – Women's Health Pipeline Products, 2010 31

Table 14: Neurocrine Biosciences, Inc. – Women's Health Pipeline Products, 2010 32

1.2 List of Figures

Figure 1: Endometriosis Therapeutics Market, Global, Revenue ($m), 2001–2009 6

Figure 2: Endometriosis Therapeutics Market, Global, Market Forecasts ($m), 2009–2017 7

Figure 3: Opportunity and Unmet Need in the Endometriosis Therapeutics Market, 2010 9

Figure 4: Strategic Competitor Assessment of the Major Marketed Products for Endometriosis, 2010 10

Figure 5: Technology Trends Analytic Framework of the Endometriosis Pipeline, 2010 16

Figure 6: Technology Trends Analytic Framework of the Endometriosis Pipeline – Description, 2010 17

Figure 7: Endometriosis Therapeutics Market – Clinical Pipeline by Mechanism Of Action, 2010 21

Figure 8: Endometriosis Pipeline by Phase of Clinical Development, 2010 21

Figure 9: Endometriosis Therapeutics Market – Strategic Competitor Assessment, 2010 24

Figure 10: Endometriosis Therapeutics Market – Clinical Pipeline by Company, 2010 25

Figure 11: GlobalData Market Forecasting Model 36

Companies mentioned

Bayer AG

Pfizer Inc.

Aeterna Zentaris Inc.

Neurocrine Biosciences, Inc.

Repros Therapeutics, Inc

Meditrina Pharmaceuticals, Inc.

To order this report:

Pathology Industry: Endometriosis - Pipeline Assessment and Market Forecasts to 2017

Pathology Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

CONTACT:

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com